Zacks CommentaryNOV 43 min read$HRTX

Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -150.00% and -0.91%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Original reporting

Zacks Commentary · Zacks Equity Research

Published Nov 4, 2025, 2:15 PM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Nov 5, 2025, 12:02 AM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates — source image — Source · www.zacks.com

Decision brief

The 30-second read

$HRTXBearishMed

Why it matters

The earnings miss could lead to short-term selling pressure, but long-term prospects depend on upcoming product approvals and pipeline success.

Market read

The news is highly relevant for traders holding or considering trading HRTX, especially in the short term.

What to watch

Potential upcoming catalysts such as pipeline developments or strategic partnerships that might offset recent losses.

Timing: Immediate, as the earnings report was published on 2025-11-04.

Background

Heron Therapeutics reported a significant Q3 loss, missing revenue estimates, which has raised concerns among investors about its growth trajectory.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$HRTXBearishMedium confidence

Context

Heron Therapeutics' recent quarterly earnings report indicates significant losses and revenue misses, which could influence investor sentiment and stock performance.

Expected impact

Likely short-term decline of 5-10%, with potential for further downside if negative sentiment persists.

Evidence & confidence

The substantial earnings miss and revenue shortfall are typical catalysts for downward price movement, but market reaction may be tempered by broader sector trends and company-specific factors.

Market effects

Sector

Potential negative impact on biotech and pharmaceutical sectors due to earnings disappointment.

Regional

Limited regional impact; primarily affecting US-based biotech stocks.

Global

Minimal, as the news pertains to a US-focused biotech company.

Counterpoint

What could challenge this read

The stock may have already priced in the earnings disappointment, and positive news or sector recovery could lead to a rebound.

Key entities

Company
Heron Therapeutics
A biotechnology company focused on developing and commercializing therapies for cancer and other serious diseases.

Read at source ← All news

AUG 29

$FULCMed

Why Did FULC, MVIS, HRTX Stocks Plunge To 52-Week Lows Today?

Fulcrum Therapeutics (FULC) fell 51% to a 52-week low of $2.9 after halting development of its lead sickle cell disease treatment due to FDA cancer risk concerns. Heron Therapeutics (HRTX) dropped 45% to $0.44 following a court ruling invalidating key patents for CINVANTI. MicroVision (MVIS) declined 32% to $0.4 after proposing a reverse stock split to meet Nasdaq requirements.

stocktwits.com2 min

AUG 17

$HRTXMedAI 8/10

Heron (HRTX) Q2 2026 Earnings Call Transcript

Heron Therapeutics (HRTX) reported Q2 2026 net revenue of $37.7M, up from $34.7M in Q1 but below expectations. CINVANTI was $21.8M, ZYNRELEF $11.1M (+35% YoY), and APONVIE $4.2M (+74% YoY). After a June patent ruling, the company amended its Hercules credit facility, resetting covenants through 2027 and reducing principal. It withdrew full-year 2026 guidance.

yahoo.com7 min

AUG 10

$HRTXMedAI 8/10

Heron Therapeutics Q2 Earnings Call Highlights

Heron Therapeutics (NASDAQ:HRTX) reported Q2 sales of about $4.2M for APONVIE, up 26% QoQ and 74% YoY, and $21.8M for CINVANTI, down about 10% YoY. SUSTOL contributed $0.5M as wind-down continued. Heron posted a Q2 net loss of $5.5M, gross margin 69.3%, and ended with $42.7M cash equivalents. It amended its Hercules credit facility with a $13.5M principal reduction and potential $4M more, and withdrew 2026 guidance.

yahoo.com6 min

AUG 10

$HRTXMed

HERON THERAPEUTICS, INC. /DE/ (HRTX): Results of Operations and Financial Condition

HERON THERAPEUTICS, INC. /DE/ (HRTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Heron Therapeutics Announces Second Quarter 2026 Financial Results - Q2 2026 net revenue of $37.7 million, up 9% from the first quarter of 2026; ZYNRELEF ® net revenue grew 35% and APONVIE ® net revenue grew 74% year-over-year - Amended credit facility with Hercules

SEC EDGAR 8-K6 min

SEP 8

$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

yahoo.com3 min